Literature DB >> 21947262

[Secondary and tertiary prevention of urological tumors].

B J Schmitz-Dräger1, G Lümmen, E Bismarck, C Fischer.   

Abstract

The amount and quality of available data on secondary and tertiary prevention of urological tumors are to a large extent unsatisfactory. In the areas of nutrition and supplementary diet the consumption of tomatoes and especially tomato products could have a beneficial effect on the course of the disease for patients with prostate cancer, whereas there is evidence that the consumption of foodstuffs containing calcium (milk and milk products) and linolenic acid as well as a fat-rich diet accelerate tumor progression. Despite as yet unsatisfactory data, men with urothelial tumors or prostate cancer should abstain from smoking and undertake sports activities. For medicinal measures the administration of 5-alpha-reductase inhibitors and bone-promoting substances for patients with prostate cancer are under discussion. The effectiveness of the substances zoledronate and denosumab has been demonstrated in prospective randomized studies. The authors recommend that the scientifically neglected field of tertiary prevention of urological tumors should in future be included as a core factor of scientific investigations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947262     DOI: 10.1007/s00120-011-2703-7

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  25 in total

Review 1.  Does smoking status influence the prognosis of bladder cancer? A systematic review.

Authors:  P Aveyard; P Adab; K K Cheng; D M A Wallace; K Hey; M F G Murphy
Journal:  BJU Int       Date:  2002-08       Impact factor: 5.588

2.  Risk factors for prostate cancer incidence and progression in the health professionals follow-up study.

Authors:  Edward Giovannucci; Yan Liu; Elizabeth A Platz; Meir J Stampfer; Walter C Willett
Journal:  Int J Cancer       Date:  2007-10-01       Impact factor: 7.396

3.  Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia.

Authors:  James R Marshall; Wael Sakr; David Wood; Donna Berry; Catherine Tangen; Felicia Parker; Ian Thompson; Scott M Lippman; Ronald Lieberman; David Alberts; David Jarrard; Charles Coltman; Peter Greenwald; Lori Minasian; E David Crawford
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-08       Impact factor: 4.254

4.  Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer.

Authors:  Rianne J M Lammers; Wim P J Witjes; Kees Hendricksen; Christien T M Caris; Maria H C Janzing-Pastors; J Alfred Witjes
Journal:  Eur Urol       Date:  2011-07-14       Impact factor: 20.096

Review 5.  Bisphosphonates for breast cancer.

Authors:  N Pavlakis; Rl Schmidt; M Stockler
Journal:  Cochrane Database Syst Rev       Date:  2005-07-20

6.  Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.

Authors:  Fred Saad; Yin-Miao Chen; Donald M Gleason; Joseph Chin
Journal:  Clin Genitourin Cancer       Date:  2007-09       Impact factor: 2.872

7.  Calcium, dairy foods, and risk of incident and fatal prostate cancer: the NIH-AARP Diet and Health Study.

Authors:  Yikyung Park; Panagiota N Mitrou; Victor Kipnis; Albert Hollenbeck; Arthur Schatzkin; Michael F Leitzmann
Journal:  Am J Epidemiol       Date:  2007-10-12       Impact factor: 4.897

Review 8.  The use of PSA as biomarker in nutritional intervention studies of prostate cancer.

Authors:  Wytske M van Weerden; Fritz H Schröder
Journal:  Chem Biol Interact       Date:  2007-11-22       Impact factor: 5.192

9.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506

10.  Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Authors:  M Dror Michaelson; Donald S Kaufman; Hang Lee; Francis J McGovern; Philip W Kantoff; Mary Anne Fallon; Joel S Finkelstein; Matthew R Smith
Journal:  J Clin Oncol       Date:  2007-03-20       Impact factor: 44.544

View more
  1 in total

1.  [Secondary prevention in patients with superficial urothelial carcinoma].

Authors:  T J Schnöller; F Zengerling; C Hirning; F Jentzmik
Journal:  Urologe A       Date:  2015-07       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.